Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Experts Highlight Developments in Lung, GI Cancers

Brandon Scalea
Published: Monday, Dec 10, 2018

Roy Herbst, MD, PhD

Roy Herbst, MD, PhD

Recent data have moved the needle across the board in oncology, with immunotherapy and targeted agents paving the way for an improvement in survival outcomes. In a panel discussion at the 36th Annual CFS®, key opinion leaders in metastatic non–small cell lung cancer (NSCLC) and gastrointestinal cancer discussed how to distinguish between the available treatments and create a more personalized approach.

Lung Cancer

There have been a number of recent changes in the management of metastatic NSCLC, and the next challenge is determining an established standard for each line of therapy, said Roy S. Herbst, MD, PhD.

“Overall, these data with immunotherapy have been huge,” said Herbst. “Just last year, we still had pundits debating whether or not these agents would actually take over how we treat NSCLC. Now, there is no debate.”

GI Cancers

Following the lung cancer portion of the session, Cathy Eng, MD, and David H. Ilson, MD, discussed the management of metastatic colorectal cancer (mCRC) and gastric cancer/gastroesophageal junction (GEJ) adenocarcinoma.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication